[Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
Spinal and bulbar muscular atrophy (SBMA) is an X-linked neurodegenerative disease caused by the expansion of a CAG repeat in the first exon of the androgen receptor (AR) gene. To date, eight CAG-repeat diseases have been identified, including spinal and bulbar muscular atrophy (SBMA). Huntington's disease (HD), dentatorubralpallidoluysian atrophy (DRPLA) and five spinocerebellar ataxias (SCAs 1, 2, 3, 6, 7). These disorders likely share a common pathogenesis caused by the gain of a toxic function associated with the expanded polyglutamine tract. Several mechanisms have been postulated as a pathogenic process for neurodegeneration caused by the expanded polyglutamine tract. Processing of the polyglutamine containing proteins by proteases liberate truncated polyglutamine tract, which may cause neurodegeneration as demonstrated in transgenic mice and transfected cells. In addition to cellular toxicity, truncated and expanded polyglutamine tracts have been shown to form intranuclear inclusions (NI). The NIs formed by the disease protein are a common pathological feature of these diseases. In SBMA, NIs containing AR protein have been observed in regions of SBMA central nervous system susceptible to degenerations. Transcriptional factors or their cofactors, such as cerb or creb-binding protein (CBP) sequestrated in the NI may alter the major intracellular transcriptional signal transduction, and ultimately may result in neuronal degeneration. The ubiquitin-proteasome pathway may also contribute to the pathogenesis of CAG-repeat diseases. As for the therapeutic strategies, many possibilities have been demonstrated. Overexpression of Hsp70 and Hsp40 chaperones act together to protect a cultured neuronal cell model of SBMA from a cellular toxicity of expanded polyglutamine tract.
Sobue
G
G
Department of Neurology, Nagoya University School of Medicine.
D000818:Animals; D050882:CREB-Binding Protein; D018840:HSP70 Heat-Shock Proteins / Q000627:therapeutic use; D006801:Humans; D002479:Inclusion Bodies / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D018832:Molecular Chaperones / Q000627:therapeutic use; D020966:Muscular Disorders, Atrophic / Q000235:genetics / Q000628:therapy; D009410:Nerve Degeneration; D009687:Nuclear Proteins / Q000502:physiology; D010455:Peptides / Q000378:metabolism; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D015534:Trans-Activators / Q000502:physiology; D018911:Trinucleotide Repeats
D018840:HSP70 Heat-Shock Proteins; D018832:Molecular Chaperones; D009687:Nuclear Proteins; D010455:Peptides; D011944:Receptors, Androgen; D015534:Trans-Activators; C097188:polyglutamine; D050882:CREB-Binding Protein; C494363:CREBBP protein, human; C494364:Crebbp protein, mouse